In March, Bob Wachter, chair of the department of medicine at the University of California, San Francisco, tweeted that those trying to time their second booster with a surge in cases were like investors timing their share purchases with a stock market rally-a strategy “which rarely works.” After that recommendation, Pfizer told NBC News that it would have such a vaccine ready for distribution by October. Food and Drug Administration recommended that the next round of booster shots target BA.4 and BA.5, the highly transmissible strains of Omicron that now dominate the U.S. Vaccine manufacturers may tailor boosters even further. Moderna’s Omicron booster produced 1.75 times as many antibodies against BA.1 as its current version. Pfizer claimed that its Omicron vaccine produced as much as three times as many antibodies against BA.1 as its current COVID vaccine one month after injection. in January.īoth manufacturers have released data that show that an Omicron booster creates a greater number of neutralizing antibodies against Omicron than the current versions of the vaccine. Those considering getting a fourth dose of the vaccine face a choice: Should they get their second booster now, in hopes of protecting themselves from this new wave of BA.5 infections? Or should they wait until new vaccines that specifically target Omicron and its subvariants are available, perhaps this fall?īoth Moderna and Pfizer say they’re close to releasing new booster shots to the public-pending regulatory approval-that target the BA.1 subvariant of Omicron, which was dominant in the U.S.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |